A Review of the Clinical Pharmacokinetics of Meloxicam

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Meloxicam is a new preferential cyclooxygenase-2 (COX-2) inhibitor currently for the treatment of osteoarthritis and rheumatoid arthritis. Its pharmacokinetic profile is characterized by a prolonged and almost complete absorption and the drug is >99.5% bound to plasma proteins. Meloxicam is metabolized to four biologically inactive main metabolites, which are excreted in both urine and faeces. The elimination half-life (t½) of meloxicam is ∼20 h. This is reflected in a total plasma clearance (CL) of 0.42 – 0.481/h. Steady-state plasma concentrations are achieved within 3—5 days. The pharmacokinetic parameters of meloxicam are linear over the dose range 7.5–30 mg and bioequivalence has been shown for a number of different formulations. No interactions were observed following the concomitant administration of food, cimetidine, antacid, aspirin, β-acetyldigoxin, methotrexate, warfarin or furosemide. Neither hepatic insufficiency nor moderate renal dysfunction have any relevant effects on the pharmacokinetics of meloxicam and dosage adjustments in the elderly are not required.

This publication has 7 references indexed in Scilit: